Carregant...
Uveal Effusion After Immune Checkpoint Inhibitor Therapy
IMPORTANCE: Immune checkpoint inhibitors, including antiprogrammed cell death protein-1 (anti-PD-1) and antiprogrammed cell death ligand-1 (anti-PD-L1) monoclonal antibodies, have recently been introduced as a promising new immunotherapy for solid cancers. The adverse effects typically include infla...
Guardat en:
| Publicat a: | JAMA Ophthalmol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Medical Association
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6145660/ https://ncbi.nlm.nih.gov/pubmed/29677240 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaophthalmol.2018.0920 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|